Showing 6981-6990 of 9883 results for "".
- Website Launches for Those Suffering from Acne Scarshttps://practicaldermatology.com/news/20141003-website_launches_for_those_suffering_from_acne_scars/2459097/A new website has launched to help those who suffer from the physical and emotional impacts of acne scarring. “A Scar Free Me” is the first of its kind online community that offers free resources and support for people coping with the aftermath of acne. Visitors can consult with skin car
- Mission Pharmacal Unveils New Lotion for Seborrheic Dermatitishttps://practicaldermatology.com/news/20140930-mission_pharmacal_unveils_new_lotion_for_seborrheic_dermatitis/2459100/To help bring a treatment option to people afflicted with common skin disorders including seborrheic dermatitis (SD), Mission Pharmacal Company has unveiled Ovace Plus Lotion (sodium sulfacetamide 9.8%). Ovace Plus Lotion joins Ovace Plus Wash (sodium sulfacetamide 10%) Cleansing Gel and Ovace Plus
- Taclonex Granted New Indication for Scalp Plaque Psoriasis in Adolescent Patientshttps://practicaldermatology.com/news/20140930-combination_topical_treatment_approved_for_scalp_plaque_psoriasis_in_adolescent_patients/2459101/LEO Pharma Inc., has received a new indication for Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension for a topical combination treatment of plaque psoriasis of the scalp in patients 12 to 17 years. The new indication represents the first indication for adolescent patients a
- GSK Presents Updated Results from Phase III BREAK-3 Study of Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140929-gsk_presents_updated_results_from_phase_iii_break-3_study_of_tafinlar_dabrafenib/2459102/Results from the planned analysis of the Phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma show benefit for the use of GSK's Tafinlar (dabrafenib) over dacarbazine (DTIC). Forty-five percent of patients treated with dabrafenib only were alive at two
- Celgene's Otezla Approved for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/20140924-celgenes_otezla_approved_for_moderate_to_severe_plaque_psoriasis/2459107/The FDA has approved Celgene's Otezla (apremilast), an oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. Otezla is the first and only PDE4 inhibitor approved for th
- Provectus Biopharmaceuticals Appoints Christopher Kaplan to Its Strategic Advisory Boardhttps://practicaldermatology.com/news/20140922-provectus_biopharmaceuticals_appoints_christopher_kaplan_to_its_strategic_advisory_board/2459110/Christopher Kaplan, currently President of Cajetan, LLC, will now be appointed to Provectus Biopharmaceuticals Strategic Advisory Board. Mr. Kaplan started his pharmaceutical career at Bristol-Myers Squibb Company. He moved quickly through various roles in US sales and sales management and
- ASDS Hires Director of Federal Advocacy and Practice Supporthttps://practicaldermatology.com/news/20140922-asds_hires_director_of_federal_advocacy_and_practice_support/2459113/The American Society for Dermatologic Surgery Association is adding its voice at the federal level. Responding to member requests to expand advocacy efforts and influence national policies that affect dermatologic surgery, ASDSA recently added a new position: Director of Federal Advocacy and Pr
- The ISDS Awards Scholarships to Young Doctors from Around the Worldhttps://practicaldermatology.com/news/20140917-the_isds_awards_scholarships_to_young_doctors_from_around_the_world/2459117/20 young doctors have been awarded generous scholarships from twenty leaders of the International Society for Dermatologic Surgery (ISDS) to attend an ISDS medical conference. This year, the scholarships were awarded to young doctors from Europe, Asia, Latin America (including Cuba), and
- MELA Sciences to Provide Corporate Overview at the Craig-Hallum Capital Group's 2014 Alpha Select Conferencehttps://practicaldermatology.com/news/20140917-mela_sciences_to_provide_corporate_overview_at_the_craig-hallum_capital_groups_2014_alpha_select_conference/2459118/Rose Crane, CEO of MELA Sciences, will provide a corporate overview at the Craig-Hallum Capital Group's 2014 Alpha Select Conference in New York City. Crane will discuss the latest FDA Pre-Market Approval of the MelaFind® System. To learn more go to:
- Late Stage Skin Cancers on the Rise in the UK: World Congress on Cancers of the Skinhttps://practicaldermatology.com/news/20140917-late_stage_skin_cancers_on_the_rise_in_the_uk_world_congress_on_cancers_of_the_skin/2459119/Advanced-stage skin cancers are on the rise in the UK, according to two studies presented this month at the World Congress on Cancers of the Skin in Edinburgh, Scotland. The findings highlight an urgent need to publicise self-check and early detection messages, the The Skin Cancer Foundation says.